오리엔트바이오 Stock: price and insider trades · South Korea

오리엔트바이오, classified in the Health Care sector, is a listed company. Its insiders report their share dealings to DART (FSS). The last twelve months, up to 2 November 2026, brought 11 filings signed by 3 insiders.

Purchases and sales both appear in the filings: 5 purchases (1 insider) and 4 sales (3 insiders). No amount is published for 9 filings, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Those buying include 1 major shareholder.

Compared with its exchange (2,655 companies, median 7 filings), a count of 11 filings is above the norm. Our records for 오리엔트바이오 go back to 2025, with 5 purchases and 4 sales on the open market in total.

The latest purchase dates back some time: it was published 67 days ago, on 4 September 2026. Filings reach the DART (FSS) feed a median of 7 days after the trade. This delay matters because a trade only becomes useful information once it is public.

For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and UCB. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.